

## Accreditation and Designation Statements and Disclosure Report

UMDF Mitochondrial Medicine 2023

### **Live Activity:**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the United Mitochondrial Disease Foundation. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the live format for this educational activity for a maximum of *19.50 AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

### **Enduring Activity:**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the United Mitochondrial Disease Foundation. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of *14.50 AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Live activity dates: June 28, 2023 – July 1, 2023

Enduring activity dates: December 22, 2023 – December 22, 2026

**The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:**

| Full Legal Name      | Commercial Interest   | Role                                          | Level of participation in the activity |
|----------------------|-----------------------|-----------------------------------------------|----------------------------------------|
| Yair Anikster        | Beam Therapeutics     | Clinical Advisor                              | Speaker                                |
| Jonathan R. Brestoff | LUCA Science, Inc.    | Scientific Advisory Board                     | Speaker                                |
| Pinchas Cohen        | CohBar Inc.           | Consultant                                    | Speaker                                |
| Stephen Carl Ekker   | LEAH Labs<br>Immusoft | Shareholder and Board Director<br>Shareholder | Speaker                                |

|                     |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                    |                  |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
|                     | <p>Primera Therapeutics</p> <p>OpenTrons Labworks<br/>LifEngine Technologies<br/>Inc</p> <p>Recombinetics</p>                                                                                                                                                                                     | <p>Mayo Clinic and I have a financial interest due to patent and know-how licensed to Primera Therapeutics</p> <p>Hold options for shares</p> <p>CEO and shareholder</p> <p>Shareholder</p>                                                        |                  |
| Amel Karaa          | Sanofi                                                                                                                                                                                                                                                                                            | Academic compensation                                                                                                                                                                                                                              | Planner-Reviewer |
| Mary Kay Koeng      | <p>Acadia Pharmaceuticals</p> <p>Jazz Pharmaceuticals</p> <p>EryDel SpA</p> <p>PTC Therapeutics</p> <p>Noema Pharma</p> <p>Marinus Pharmaceuticals</p> <p>GW Research Ltd</p> <p>Nflexion Therapeutics</p> <p>Stealth Biotherapeutics</p> <p>Astellas Pharma Inc</p> <p>Reneo Pharmaceuticals</p> | <p>Advisor</p> <p>Advisor, Consultant, Speaker, Researcher</p> <p>Researcher</p> <p>Researcher</p> <p>Researcher</p> <p>Researcher</p> <p>Researcher</p> <p>Researcher</p> <p>Researcher</p> <p>Researcher</p> <p>Researcher</p> <p>Researcher</p> | Planner-Reviewer |
| James D McCully     | cellvie Inc.                                                                                                                                                                                                                                                                                      | Founder and Board Member                                                                                                                                                                                                                           | Speaker          |
| Robert K. Naviaux   | Paxmedica<br>Kuzani                                                                                                                                                                                                                                                                               | Consultant<br>Consultant                                                                                                                                                                                                                           | Speaker          |
| Jared Rutter        | Pfizer                                                                                                                                                                                                                                                                                            | Sponsored research agreement                                                                                                                                                                                                                       | Speaker          |
| Shiladitya Sengupta | <p>Vyome Therapeutics Inc</p> <p>Alyssum therapeutics</p> <p>Famy life science</p> <p>Advamedica inc</p> <p>Invictus inc</p>                                                                                                                                                                      | <p>Founder, board member, consultant</p> <p>Founder, board member, consultant</p> <p>Director, consultant</p> <p>Member of SAB, consultant</p> <p>Founder, board member</p>                                                                        | Speaker          |

|                      |                                                                                                        |                                                                                                                                         |                  |
|----------------------|--------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Douglas C. Wallace   | Pano Therapeutics<br>Medical Excellence<br>Capital                                                     | Scientific Advisory<br>Board<br>Scientific Advisory<br>Board                                                                            | Planner-Reviewer |
| Susan R Weiss        | Pfizer<br><br>Ocugen<br><br>Immunome<br><br>Arbutus<br>Merck                                           | Consultant<br>Scientific Advisory<br>Board<br>Scientific Advisory<br>Board<br>Fee for service<br>agreement with my<br>lab<br>Consultant | Speaker          |
| Ethan Oren Perlstein | Perlara PBC<br>Maggie's Pearl                                                                          | CEO<br>CEO                                                                                                                              | Speaker          |
| Fernando Scaglia     | PTC Therapeutics<br>Astellas Pharma<br>Saol Therapeutics<br>Precision BioSciences<br>Acer Therapeutics | Researcher<br>Researcher<br>Researcher<br>Consultant<br>Consultant                                                                      | Planner-Reviewer |
| Robert Schwartz      | Miromatrix Inc.<br><br>Lime Therapeutics<br>Alnylam<br>Pharmaceuticals                                 | Scientific Advisory<br>Board<br>Scientific Advisory<br>Board<br>Speaker and<br>Consultant                                               | Speaker          |
| Sumit Parikh         | Astellas<br>Pharmaceuticals<br>Acadia<br>Pharmaceuticals<br><br>CHAMP Foundation                       | Drug study fund to<br>institution<br>Drug study fund to<br>institution<br><br>Natural history study                                     | Speaker          |

*"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."*

These financial relationships with ineligible companies have been mitigated by PeerPoint Medical Education Institute and the United Mitochondrial Disease Foundation.

**All other presenters, planners, editors, or staff report no relationships to disclose:**

*"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."*

